Scope:Specific Challenge The final lot testing for safety and potency of established vaccines often suffers from inaccuracies due to the inherent variability of the animal tests used. Recent advances in quality and process control and modern vaccines of well-defined composition suggest that quality and safety control of the final product may be possible without in vivo safety and potency testing. Scope The Consistency Approach is a new paradigm for improved quality control of vaccines aiming at an integrated quality monitoring programme during vaccine lot production using non-animal methods. The main objective is to demonstrate the proof-of-concept of this new paradigm and its relevance to both the human and veterinary vaccine sectors. Expected Impact
It is expected that achieving the main objective would lead to an agreed road map for translating the Consistency Approach into regulatory guidance. In addition the project could contribute to the access to medicines, reducing lead time and cost, improving R&D processes beyond vaccine manufacturing.
Budget
IMI contribution: EUR 7 850 000
EFPIA contributi...
ver más
Scope:Specific Challenge The final lot testing for safety and potency of established vaccines often suffers from inaccuracies due to the inherent variability of the animal tests used. Recent advances in quality and process control and modern vaccines of well-defined composition suggest that quality and safety control of the final product may be possible without in vivo safety and potency testing. Scope The Consistency Approach is a new paradigm for improved quality control of vaccines aiming at an integrated quality monitoring programme during vaccine lot production using non-animal methods. The main objective is to demonstrate the proof-of-concept of this new paradigm and its relevance to both the human and veterinary vaccine sectors. Expected Impact
It is expected that achieving the main objective would lead to an agreed road map for translating the Consistency Approach into regulatory guidance. In addition the project could contribute to the access to medicines, reducing lead time and cost, improving R&D processes beyond vaccine manufacturing.
Budget
IMI contribution: EUR 7 850 000
EFPIA contribution: EUR 7 850 000
Total: EUR 15 700 000
ver menos
Características del consorcio
Características del Proyecto
Características de la financiación
Información adicional de la convocatoria
Otras ventajas